thought call
solid commerci perform catalyst start look improv sentiment
despit sign commerci strength recent posit read-out see
 thought jakafi data share remain flat
sinc end under-perform broader market
peer nbi contrast like continu neg sentiment
fda restrict olumi approv overhang stock
continu see upsid given strong base busi anchor jakafi
y/i continu experi robust patient growth current mf
pv indic y/i well attract divers late-stag pipelin
set begin provid near-term top-lin contribut start steroid refractori
activ gvhd beyond sndawhich remain track snda
submiss breakthrough design follow plan launch immedi
addit opportun expand indic may open read-out
jakafi studi steroid refractori itacitinib
steroid nave littl upsid studi reflect current share price
along rest pipelin includ notabl late stage asset inhibitor
fgfr inhibitor pemigatinibw continu see opportun sentiment
improv follow rang development regulatori catalyst expect
begin combin strength core busi continu see
compel risk/reward profil share justifi ow rate pt
pipelin updat data jakafi refractori mf comfort
expect read-out monotherapi r/r fl mzl mcl trial like
nda pemigatinib cholangiocarcinoma still anticip data
bladder cancer like next year
model chang given trend commentari modestli increas
forecast vs prior vs prior
estim non-gaap ep vs prior vs prior
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight compel mix
grow commerci asset interest pipelin
asset exclud epacadostat
epacadostat key pipelin driver compani
earlier pipelin program could result
share upsid also expect jakafi peak
royalti baricitinib repres
ww compel commerci perform
success earlier pipelin asset across portfolio
ww compel commerci perform
success earlier pipelin asset across portfolio
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
